M&A Deal Summary

LumiThera Acquires MacuLogix

On July 26, 2022, LumiThera acquired medical products company MacuLogix

Acquisition Highlights
  • This is LumiThera’s 2nd transaction in the Medical Products sector.
  • This is LumiThera’s 2nd transaction in the United States.
  • This is LumiThera’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2022-07-26
Target MacuLogix
Sector Medical Products
Buyer(s) LumiThera
Deal Type Add-on Acquisition

Target

MacuLogix

Middletown, Pennsylvania, United States
MacuLogix is a provider of equipment to eye care professionals with the instrument, tools, and education needed to effectively manage patients with age-related macular degeneration (AMD) by leveraging the science of dark adaptation through its AdaptDx and AdaptDx Pro. MacuLogix is based in Middletown, Pennsylvania.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

LumiThera

Poulsbo, Washington, United States
Category Company
Sector Medical Products
DESCRIPTION

LumiThera is a commercial-stage medical device company focused on treating people affected by ocular damage and disease including dry age-related macular degeneration, a cause of blindness in adults over 65. The company uses PBM for the treatment of visual disorders and is commercializing the office-based Valeda Light Delivery System to be used by eye care providers as medical treatment. LumiThera is based in Poulsbo, Washington.

DEAL STATS #
Overall 2 of 2
Sector (Medical Products) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Pennsylvania) 1 of 1
Country (United States) 2 of 2
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-11 Diopsys

Pine Brook, New Jersey, United States

Diopsys is involved in providing modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders. The company provides both Visual Evoked Potential (VEP) and ERG vision testing technology. It is this technology that powers Diopsys, Inc.'s medical devices – the Diopsys NOVA, Diopsys ARGOS, and Diopsys RETINA PLUS ERG and VEP Vision Testing System product series and the Enfant Pediatric VEP Vision Testing System. Diopsys was formed in 1998 and is based in Pine Brook, New Jersey.

Buy -
Mergr

Product

Company

Legal